Study shows Nattopharma vitamin K2 MK-7 improves endothelial function

The aim of the study was to examine the effects of vitamin K2 MK-7 on endothelial dysfunction, in ApoE/LDLR -/- mice at varying stages of disease development

A study has been published showing K2 as MK-7 boosts nitric oxide (NO), improving NO-dependent endothelial function. Adding to the already-strong body of clinical evidence confirming Vitamin K2 as MK-7 inhibits arterial calcification and acts as an antioxidant, the study in Vascular Pharmacology used MenaQ7 Vitamin K2 as MK-7, supplied by NattoPharma.

Endothelial dysfunction has been associated with many health issues, including being a well-established response to cardiovascular risk factors and precedes the development of atherosclerosis, a disease of the arteries characterised by the creation of plaques and by vascular inflammation fatty material on the inner walls. Given the fact that endothelial function determines cardiovascular health, researchers hypothesised that the positive effects of vitamin K2 intake on cardiovascular mortality could be linked to the vitamin K-dependent regulation of endothelial function.

According to researchers, "The aim was to examine the effects of vitamin K2 - MK-7 on endothelial dysfunction, in ApoE/LDLR -/- mice at the early and late stages of disease development, in the absence and in the presence of atherosclerotic plaques, respectively."

The study found K2 as MK-7 boosts nitric oxide (NO), improving NO-dependent endothelial function

"We are incredibly encouraged by the results of this study highlighting new pharmacological activity of Vitamin K2 as MK-7," explained Hogne Vik, NattoPharma Chief Medical Officer.

In ApoE/LDLR -/- mice at the stage prior to atherosclerosis development, four-week treatment with K2-MK-7, given at a low dose (0.05 mg/kg), "improved acetylcholine- and flow-induced, endothelium-dependent vasodilation in aorta or in femoral artery, as assessed in vivo by MRI. This effect was associated with an increased NO production, as evidenced by EPR measurements in ex vivo aorta."

The study concluded that low dose of Vitamin K2 - MK-7 compatible with effective doses for K2 - MK-7 recommended for humans, to provide benefits for cardiovascular health, plays an important role in the regulation of endothelial function.

"The study demonstrated that vitamin K2 - MK-7 improved NO-dependent endothelial function in mice, and the results showed that K2 - MK-7 provided a vaso-protective effect independently whether endothelial dysfunction was treated with vitamin K2 - MK-7 prior to or concurrently with the occurrence of atherosclerotic plaques," explained Vik. "This contributes nicely to our already substantial body of research showing MenaQ7 is a cardio-protective nutrient, and reaffirms why the medical community is interested in ongoing study of this important nutrient for the betterment of global health."

Nattopharma said that the paper is significant because it adds to the growing body of cardiovascular evidence for MenaQ7, identifying the endothelial profile of the pharmacological activity of K2, which had not previously been described. Also noteworthy is that Kaydence Pharma, the pharmaceutical spin off of NattoPharma, used this data to submit for a new cardiovascular patent.

Companies